Clinical Trial Update: Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study results for dasatinib in relapsed small cell lung cancer are reported (includes extensive stage, limited stage, and recurrent disease).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-04-26